- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
London-based AstraZeneca reported quarterly earnings on Thursday of $1.56 per share. While the results beat the expectations of analysts polled by Thomson Reuters by 21 cents, the company’s core earnings fell 3 percent from the year-ago quarter. The pharmaceutical company only avoided a much larger drop by lowering costs and securing a favorable tax adjustment. Its drop in sales was much worse than the decrease in earnings; they declined 16 percent to $7.28 billion, but beat analysts’ estimates of $7.20 billion…
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.